Patents Assigned to IPSOGEN, SAS
  • Publication number: 20130079234
    Abstract: A method for predicting the sensitivity of tumor cells to an anthracycline-based chemotherapy includes determining the differential expression level of a MYBL2 gene in tumors cells. A polynucleotide library is useful to predict the sensitivity of tumor cells to an anthracycline-based chemotherapy and includes a pool of polynucleotide sequences or subsequences thereof wherein the sequences or subsequences correspond substantially to any of the polynucleotide sequences SEQ ID No: 308, SEQ ID No: 309 and/or SEQ ID No: 310 or the complements thereof.
    Type: Application
    Filed: May 26, 2011
    Publication date: March 28, 2013
    Applicants: Institut Paoli-Calmettes, IPSOGEN, SAS
    Inventors: Francois Bertucci, Rémi Houlgatte, Daniel Birnbaum, Catherine Nguyen, Patrice Viens, Vincent Fert
  • Publication number: 20110086765
    Abstract: Method for molecular characterization of a carcinoma including: (i) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a first group determining expression level of the polynucleotide from the first group to differentiate a tumor in which a lymph node has been invaded by a tumor cell from a tumor in which a lymph node has not been invaded by a tumor cell; (ii) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a second group determining expression level of the polynucleotide from the second group to distinguish tumors sensitive to anthracycline from tumors insensitive to anthracycline; (iii) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a third group determining expression levels of the polynucleotide from the third group to classify good and poor prognosis primary breast tumors.
    Type: Application
    Filed: October 13, 2010
    Publication date: April 14, 2011
    Applicants: IPSOGEN, SAS, Institut Paoli-Calmettes
    Inventors: Francois Bertucci, Rémi Houlgatte, Daniel Birnbaum, Catherine Nguyen, Patrice Viens, Vincent Fert
  • Publication number: 20050221398
    Abstract: A method for analyzing differential protein expression associated with histopathologic features of breast disease including detecting overexpression or underexpression of a pool of proteins in breast tissues or cells, the pool including at lease one of a protein set including Afadin, Aurora A, a-Catenin, b-Catenin, BCL2, Cyclin D1, Cyclin E, Cytokeratin 5/6, Cytokeratin 8/18, E-Cadherin, EGFR, ERBB2, ERBB3, ERBB4, Estrogen receptor, FGFR1, FHIT, GATA3, Ki67, Mucin 1, P53, P-Cadherin, Progesterone receptor, TACC1, TACC2, TACC3, Cytokeratin 6, Cytokeratin 18, Ang1, AuroraB, BCRP1, CathepsinD, CD10, CD44, CK14, Cox2, FGF2, GATA4, Hif1a, MMP9, MTA1, NM23, NRG1a, NRG1beta, P27, Parkin, PLAU, S100, SCRIBBLE, Smooth Muscle Actin, THBS1 and TIMP1.
    Type: Application
    Filed: January 18, 2005
    Publication date: October 6, 2005
    Applicants: Ipsogen, SAS, a corporation of France, INSERM, a corporation of France, Institut Paoli-Calmettes, a corporation of France
    Inventors: Jocelyne Jacquemier, Francois Bertucci, Daniel Birnbaum, Stephane Debono, Rebecca Tagett